Ethan B.’s Post

Today on World Lung Cancer Day, we want to raise awareness of the most aggressive form of lung cancer: Small Cell Lung Cancer (#SCLC). At DISCO Pharmaceuticals GmbH, using our target discovery platform, we have completed the first-ever mapping of the SCLC #surfaceome. This has revealed countless novel proteins and protein communities on the surface of SCLC cells providing target🎯candidates for mono- and bi-specific #antibodytherapeutics Using this knowledge, we have launched the development of SCLC target-specific therapeutics to improve #patient care by providing more effective, targeted treatment options. To learn more about our cell surfaceome discovery technology, visit the link in the comments below. #WorldLungCancerDay #WLCD2024 #LungCancerAwareness #SmallCellLungCancer

Exciting times at Abdera Therapeutics! The U.S. FDA has given the green light 🚦 to the Investigational New Drug (IND) application for ABD-147, a revolutionary Radiopharmaceutical treatment for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Abdera's innovative ROVEr™ platform, ABD-147 is a precision radiopharmaceutical poised to transform cancer treatment. This novel therapy targets DLL3 - a marker on aggressive neuroendocrine tumors, sparing normal cells. The gears are in motion to launch a Phase 1 clinical trial in late 2024. #FDA #Radiopharmaceuticals #Biotechnology #Neuroendorcinecarcinoma #Cancer #Oncology #SCLC #ClinicalDevelopment #CancerResearch #NuclearMedicine

#Merck & Co Inc (NYSE:MRK) announced on Thursday that its investigational lung cancer therapeutic combination of pembrolizumab (Keytruda) and vibostolimab failed to meet the goal of a mid-stage study. Vibostolimab is an investigational anti-TIGIT antibody that Merck said restores antitumor activity by blocking the TIGIT receptor from binding to its ligands (CD112 and CD155), activating T lymphocytes that assist in destroying tumor cells. The company said the Phase 2 study of the combination therapy in previously treated patients with metastatic non-small cell lung cancer showed vibostolimab/pembrolizumab plus chemotherapy drug docetaxel extended median progression-free survival by 2.4 months compared to those treated with docetaxel alone but did not reach statistical significance. The drug combination alone also failed to improve overall survival.   More at #Proactive #ProactiveInvestors #NYSE #MRK http://ow.ly/UtmV1054XWY

Did you know that the FDA has approved 11 bispecific antibodies (bsAbs) to treat cancer?[1] Whether it's trispecifics, bsAb prodrugs, bsAbs that induce degradation of tumor targets. or bsAbs acting as cytokine mimetics, Certis Oncology partners with preclinical drug developers to understand MOA and test the efficacy of next-generation, early-stage bsAbs for the treatment of solid tumors. Contact us today to learn more: https://hubs.la/Q02Jqy0f0. #CancerResearch #Bispecifics #Antibodies #FightCancer [1]Klein C et al. The Present and Future of Bispecific Antibodies for Cancer Therapy. Nat Rev Drug Discov 23, 301–319 (2024).

Read the full case study at the link below and visit us at #ASCO24 Booth 33168 to dive deeper into our findings!

🚀 Exciting Announcement from Axella Research! 🚀 We are thrilled to share that Mirror Biologics is starting up a new Phase 2 clinical trial in collaboration with Axella Research, focusing on advanced metastatic colorectal cancer (CRC). This trial, titled "COMUNITY" (NCT06557278), combines AlloStim® with an anti-PD-L1 therapy to potentially convert "cold" tumors into "hot" ones, making them responsive to immunotherapy. Key Details: -Target: Chemotherapy and immunotherapy-refractory MSS metastatic CRC patients. -Treatment: AlloStim® in combination with Bavencio (Avelumab). -Objective: To assess safety and efficacy as a fourth-line treatment. Estimated Enrollment: 50 participants. We invite investigators and clinical research sites interested in participating in this groundbreaking study to reach out to us for collaboration opportunities. email: trials@axellaresearch.com Stay tuned for updates as we advance in this critical research! #ClinicalResearch #Oncology #Immunotherapy #AxellaResearch #MirrorBiologics #ClinicalTrials #CancerTreatment

Atossa Therapeutics announces an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Previous in silico and preclinical research determined a strong, clinically relevant, anti-tumor effect when combining the two therapies. “The work we are doing with Weill Cornell is designed to validate the in silico modeling in well-established cell culture models of breast cancer. Once we have this data, we expect to move quickly into a clinical study investigating a (Z)-endoxifen / ADC combination in patients with late-line metastatic breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. Learn more: https://lnkd.in/ekad_hWY #clinicaltrial #breastcancer, https://lnkd.in/ev6gadb7

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/eaxfqX showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/7Y36P0 🤝 #ChemoMetec #NucleoCounter #IovanceBiotherapeutics #Cellcounting

Interested in examining the relationship between baseline CD8 lymph node avidity and response to IO therapy in your trials? Higher numbers of highly CD8 PET-avid lymph nodes as well as overall higher SUV values in those lymph nodes at baseline were associated with better response to IO therapy. Reach out if interested in collaboration! #phase1 #phase2 #oncologyresearch #petct

🚀 Presenting ADC Digest for March 2024! 🚀 This week, the landscape of Antibody Drug Conjugates (ADCs) is ablaze with remarkable advancements!  🔬💊 🌍 Hansoh Pharma and Biotheus strengthen collaboration on EGFR/cMET Bispecific ADC development 🌍 Zai Lab Unveils Breakthrough ADC ZL-1310 for Solid Tumor Treatment 🌍 Pfizer eyes Adcetris Expansion into Large B-cell lymphoma following a successful trial 🌍 T-DXd exhibits intracranial activity in HER2+ breast cancer brain metastases meta-analysis Stay tuned for more updates in the world of ADCs! #ADC #Antibodydrugconjugate #antibodydrugconjugates #ADCnews #CIScientists #CompetitiveIntelligence